OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cardiology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
LIPC variant in combined hypocholesterolaemia	832
Antibody treatment to deplete transthyretin amyloid deposits in the heart	535
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	380
Intravascular imaging improves outcomes	362
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	336
Travelling with heart failure: risk assessment and practical recommendations	333
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	327
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	326
Takotsubo syndrome: pathophysiological insights and innovations in patient care	315
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	314
Genetics and mechanisms of thoracic aortic disease	265
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	256
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	252
Alternative defibrillation strategies improve outcomes	250
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	248
Detection of subclinical hypertrophic cardiomyopathy	248
Defining iron deficiency in patients with heart failure	247
European guidelines for hypertension in 2024: a comparison of key recommendations for clinical practice	242
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	231
Think Aorta: aortic dissection awareness and perspectives from the patient	222
Electron microscopy of cardiac 3D nanodynamics: form, function, future	215
Hallmarks of cardiovascular ageing	212
Neuromodulation reduces inflammation in HFpEF	202
A fatty acid from mother’s milk drives cardiomyocyte maturation in newborn mice	196
CSDE1 regulates LDL receptor levels	191

Preparticipation screening reduces SCD in young athletes	190
LDL-cholesterol lowering with obicetrapib	185
Increased degradation of desmosomal proteins in ACM	179
Identifying leukocyte phenotypes by scRNA-seq to predict cardiovascular risk	179
No benefit of apoA-I infusion after myocardial infarction	179
Catheter ablation improves outcomes in patients with AF and end-stage HF	174
Decongestion in heart failure: medical and device therapies	170
Reactive oxygen species in hypertension	167
Tailored therapeutics for cardiomyopathies	167
Graded exercise therapy should not be recommended for patients with post-exertional malaise	138
Colchicine in acute coronary syndromes: the present and the possible future	136
Targeting immune cell recruitment in atherosclerosis	130
Extracellular matrix in vascular homeostasis and disease	129
Prevention of atherosclerosis from childhood	126
The oral microbiome in the pathophysiology of cardiovascular disease	122
Treatment of mild chronic hypertension in pregnancy reduces pre-eclampsia risk	122
Donor macrophages influence rejection of transplanted hearts	119
Modelling pre-eclampsia and its cardiovascular effects	113
Reply to ‘Graded exercise therapy should not be recommended for patients with post-exertional malaise’	109
RNA interference lowers triglyceride levels	108
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine	107
Cardiac sarcomere turnover by unidirectional replacement of proteins	107
Bempedoic acid prevents cardiovascular events in statin-intolerant patients	104
Evidence does not support the reduction of added sugar intake from all food sources	101
Promising novel siRNA for the treatment of hypertension	99
Semaglutide is beneficial in patients with HFpEF and obesity	97
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials	97
An epigenome editing approach induces durable silencing of Pcsk9	94
Global epidemiology of heart failure	94
Single-cell profiles of CHD and CM	93
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight	90
BP management with a village-doctor-led strategy	90
Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation	89
Simvastatin protects against endothelial dysfunction via epigenetic mechanisms	88
Development of a miniature, bioresorbable, light-activated pacemaker	87
Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	87
The gut metabolite imidazole propionate is a potential biomarker of and therapeutic target for atherosclerosis	86
The role of the molecular autopsy in sudden cardiac death in young individuals	85
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target	85
Heart transplantation: advances in expanding the donor pool and xenotransplantation	85
Efferocytosis in atherosclerosis	81
CNR1 antagonism attenuates cannabis-induced atherosclerosis	79
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	79
Low alcohol intake might lower CVD risk by reducing stress-related brain activity	78
Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy	75
Gut bacteria can break down cholesterol	72
Baxdrostat beneficial in uncontrolled or resistant hypertension	72
Molecular gatekeepers of endogenous adult mammalian cardiomyocyte proliferation	70
PCSK9 inhibition for primary prevention of cardiovascular events	69
Gene–environment interactions in the pathogenesis of cardiovascular disease	66

Improving medication adherence in cardiovascular disease	66
New insights into dietary cholesterol absorption	65
Cardiovascular disease and cancer: shared risk factors and mechanisms	64
Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis	63
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	62
Renal denervation for hypertension	61
Mechanisms and treatment of pulmonary arterial hypertension	61
Cardiovascular benefits of fermented foods and beverages: still up for debate	59
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis	59
Pacing with respiratory sinus arrhythmia improves outcomes in heart failure	59
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia	56
Cardiac optogenetics: controlling the heart with light	55
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	51
The need for increased pragmatism in cardiovascular clinical trials	49
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention	48
Transcriptional regulation in heart development, disease and regeneration: reassessing the fetal gene hypothesis	46
Metabolites matter for gut microbiota as a modifiable risk factor in cardiovascular diseases	45
Heart failure and obesity: novel insights leading to new treatment paradigms	44
Synthetic ion channel modulator reverses sodium channel dysfunction linked to cardiac arrhythmias	43
Integration of cardiovascular and mental health: from concepts to the clinic	43
Epigenetic editing in cardiovascular medicine: moving beyond the hype	43
Blood pressure and its variability: classic and novel measurement techniques	42
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications	42
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	42
The cardiac parasympathetic system has two parallel circuits	40
Inhibiting aldosterone synthase reduces blood pressure	39
Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women	34
Black In Cardio: promoting diversity and representation in the cardiovascular field	34
Age-induced senescence impairs the neurovascular interface in the heart	34
Gout flares can precede cardiovascular events	33
Phase separation of protein kinase A: a new paradigm in cardiac regulation?	32
ASGR1 inhibition stimulates cholesterol excretion	31
Sotatercept as add-on therapy for advanced PAH	31
Colchicine in patients with cardiovascular disease	30
Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition	27
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials	27
Artificial intelligence-enhanced echocardiography in cardiovascular disease management	27
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	27
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	26
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	26
Consequences of ionizing radiation exposure to the cardiovascular system	26
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	26
Genome editing prevents hypertrophic cardiomyopathy in mice	25
Surgery safer than endovascular therapy for CLTI	25
Imaging cAMP nanodomains in human iPSC-derived cardiomyocytes	24
Leadless and extravascular cardiac resynchronization therapy: the future for CRT?	24
Characterization of the F8 gene: a silver lining in a dark cloud	24
Preserving the future of heart transplantation	24
Effects of lifestyle factors on leukocytes in cardiovascular health and disease	23
A role for lipophagy in atherosclerosis	22
An ex vivo perfusion platform for the testing of cardiovascular interventional devices	22
Publisher Correction: Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	22
Building the Australian Cardiovascular disease Data Commons	22
A distinct platelet differentiation pathway is involved in age-related thrombocytosis	22
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	21
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	21
High troponin I levels predict death after surgery	20
Sustained BP reduction with renal denervation	20
Alain Cribier (1945–2024)	20
Implementing LGBTQ-inclusive policies for cardiology practice and the workforce	19
Charting the future of cardiology with large language model artificial intelligence	19
The dynamic cardiac cellular landscape: visualization by molecular imaging	18
Mind the gap: sex-related differences in cardiovascular disease	17
Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement from the QCI Study Group	17
Unravelling the genetic heart–brain connection using MRI	17
Cardiac splicing as a diagnostic and therapeutic target	17
Mapping the functions of IgM antibodies in atherosclerotic cardiovascular disease	17
Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity	17
Contemporary pharmacological treatment and management of heart failure	16
Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy	16
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	16
The microtubule cytoskeleton in cardiac mechanics and heart failure	16
Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine	16